HIF1A and cancer: Hypoxia‐inducible factor 1‐alpha (HIF‐1α) can induce cancer cell resistance to tamoxifen and fulvestrant treatment, and its over‐expression in ERα+ patients is associated with poor survival to endocrine therapy.56